Skip to main content

Table 2 Mixed effects, generalised linear model for ICU survival matched for propensity for use of ‘enhanced’ prophylaxis. Effect sizes are unscaled log odds (positive indicates survival benefit)

From: Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units

Term Effect size (log odds) p-value 95% CI  
(Intercept) 0.38 0.37 − 0.452 1.21
Use of ‘enhanced’ (therapeutic) prophylaxis 0.64 0.0069 0.176 1.1
Age (years) − 12.1  < 0.0001 − 15.6 − 8.69
BMI − 1.34 0.02 − 2.46 − 0.211
History of hypertension − 0.0204 0.94 − 0.53 0.489
History of diabetes − 0.07 0.83 − 0.70 0.563
History of renal disease − 0.951 0.1 − 2.1 0.198
Intubated 2.28 0.00026 1.1 3.5
D-dimer at ICU_admission − 3390 0.38 − 11,000 4180
P/F ratio at ICU admission 18.4 0.13 − 5.24 42
CRP at ICU admission − 19.8 0.26 − 54.3 14.7
Fibrinogen_at ICU_admission − 5.14 0.9 − 89.8 79.5
Platelet count at_ICU_admission 61.5 0.0004 27.7 95.4
WBC at ICU admission − 1.73 0.052 − 3.46 0.0119
Antiplatelet agent use 0.44 0.2 − 0.238 1.12
  1. BMI, body mass index; ICU, intensive care unit; P/F partial pressure of oxygen/inspired fraction of oxygen; CRP, C-reactive protein; WBC, white blood cells